双膦酸盐与特立帕肽在胸腰椎脊柱融合中的应用:比较研究的系统综述与Meta分析
该系统综述与Meta分析比较双膦酸盐或特立帕肽对胸腰椎脊柱融合患者影像学与功能结局的疗效。双膦酸盐与对照组在融合率和螺钉松动风险上无统计学显著差异,特立帕肽融合率高于双膦酸盐;双膦酸盐降低 cage 下沉和椎体骨折的比值。
要点
- 双膦酸盐与对照组融合率无统计学显著差异(OR=2.2,95%CI:0.87-5.56,P=0.09)。
- 特立帕肽融合率高于双膦酸盐(OR=2.3,95%CI:1.55-3.42,P<0.0001)。
- 双膦酸盐降低 cage 下沉和椎体骨折的比值(下沉 OR=0.29,骨折 OR=0.18)。
核心结论
- 与对照组相比,双膦酸盐似乎不损害成功的脊柱融合,尽管特立帕肽融合率高于双膦酸盐。
- 与接受脊柱融合的对照组相比,双膦酸盐降低 cage 下沉和椎体骨折的比值。
研究设计与样本
- 系统综述与Meta分析,系统检索医学参考文献数据库,纳入胸腰椎脊柱融合后使用双膦酸盐或特立帕肽的比较研究。
- 采用随机效应模型进行Meta分析以处理异质性,评估的影像学结局包括融合率、螺钉松动风险、cage 下沉和椎体骨折。
- 证据等级为3。
主要发现
- 双膦酸盐与对照组在融合率上无统计学显著差异(OR=2.2,95%CI:0.87-5.56,P=0.09)。
- 双膦酸盐与对照组在螺钉松动风险上无统计学显著差异(OR=0.45,95%CI:0.14-1.48,P=0.19)。
- 特立帕肽融合率高于双膦酸盐(OR=2.3,95%CI:1.55-3.42,P<0.0001)。
- 特立帕肽与双膦酸盐在螺钉松动风险上无统计学显著差异(OR=0.37,95%CI:0.12-1.18,P=0.09)。
- 与对照组相比,双膦酸盐降低 cage 下沉的比值(OR=0.29,95%CI:0.11-0.75,P=0.01)和椎体骨折的比值(OR=0.18,95%CI:0.07-0.48,P=0.0007)。
关键数值与推荐
- 双膦酸盐 vs 对照组融合率:OR=2.2,95%CI:0.87-5.56,P=0.09。
- 双膦酸盐 vs 对照组螺钉松动:OR=0.45,95%CI:0.14-1.48,P=0.19。
- 特立帕肽 vs 双膦酸盐融合率:OR=2.3,95%CI:1.55-3.42,P<0.0001。
- 特立帕肽 vs 双膦酸盐螺钉松动:OR=0.37,95%CI:0.12-1.18,P=0.09。
- 双膦酸盐 vs 对照组 cage 下沉 OR=0.29(95%CI:0.11-0.75,P=0.01),椎体骨折 OR=0.18(95%CI:0.07-0.48,P=0.0007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Systematic review and meta-analysis. OBJECTIVE: To compare the efficacy of the use of either bisphosphonates or teriparatide on radiographic and functional outcomes of patients that had thoracolumbar spinal fusion. SUMMARY OF BACKGROUND DATA: Controversy exists as to whether bisphosphonates interfere with successful spinal arthrodesis. An alternative osteoporosis medication is teriparatide, a synthetic parathyroid hormone that has an anabolic effect on osteoblast function. To date, there is limited comparative data on the influence of bisphosphonates or teriparatide on spinal fusion. METHODS: A systematic search of medical reference databases was conducted for comparative studies on bisphosphonate or teriparatide use after thoracolumbar spinal fusion. Meta-analysis was performed using the random-effects model for heterogeneity. Radiographic outcomes assessed include fusion rates, risk of screw loosening, cage subsidence, and vertebral fracture. RESULTS: No statistically significant differences were noted between bisphosphonates and control groups regarding fusion rate and risk of screw loosening (fusion: odds ratio [OR] = 2.2, 95% confidence interval [CI]: 0.87-5.56, P = 0.09; loosening: OR = 0.45, 95% CI: 0.14-1.48, P = 0.19). Teriparatide use was associated with higher fusion rates than bisphosphonates (OR = 2.3, 95% CI: 1.55-3.42, P < 0.0001). However, no statistically significant difference was noted between teriparatide and bisphosphonates regarding risk of screw loosening (OR = 0.37, 95% CI: 0.12-1.18, P = 0.09). Lastly, bisphosphonate use was associated with decreased odds of cage subsidence and vertebral fractures compared to controls (subsidence: OR = 0.29, 95% CI 0.11-0.75, P = 0.01; fracture: OR = 0.18, 95% CI 0.07-0.48, P = 0.0007). CONCLUSION: Bisphosphonates do not appear to impair successful spinal fusion compared to controls although teriparatide use is associated with higher fusion rates than bisphosphonates. In addition, bisphosphonate use is associated with decreased odds of cage subsidence and vertebral fractures compared to controls that had spinal fusion. LEVEL OF EVIDENCE: 3.
引用
- Buerba RA, Sharma A, Ziino C, et al. Bisphosphonate and Teriparatide Use in Thoracolumbar Spinal Fusion: A Systematic Review and Meta-analysis of Comparative Studies. Spine (Phila Pa 1976). 2018. PMID: 29462070. doi:10.1097/BRS.0000000000002608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。